Mason C. and Mary D. Rudd Endowed Chair In Neurology
Professor, Dept. of Neurology

UofL Health Care Outpatient Center
401 E. Chestnut Street, Suite 510
Louisville, KY 40292
Clinical Phone: 502-589-0802
Academic Phone: 502-852-2871

Education

City College of New York, New York
Degree: B.S., Biology

Mount Sinai School of Medicine
City University of New York
New York, New York
Degree: M.D.

Training

Straight Medicine Internship
Beth Israel Hospital
New York, New York

Neurology Residency and Chief Residency
Mount Sinai School of Medicine
New York, New York

Research Fellow, National Institutes of Health
(Senile Dementia: Biological and Behavioral Aspects)
Albert Einstein College of Medicine
New York, New York

Board Certifications

Certified, American Board of Psychiatry and Neurology

Biography

Dr Friedland is a clinical and research neurologist devoted to the study of brain disorders associated with aging. He is a graduate of the City College of New York and was a student at the University of Kentucky School of Medicine before graduating from the Mount Sinai School of Medicine in New York in 1973. He completed his neurology residency at the Mount Sinai Hospital and was a Fellow in dementia and aging at the Albert Einstein College of Medicine, NY. He then worked at the University of California, Davis, and in the Research Medicine Group of the Lawrence Berkeley Laboratory of the University California, Berkeley where he served as Chief Neurologist. From 1985 to 1990 he was Deputy Clinical Director and Chief of the Section on Brain Aging and Dementia of the National Institute on Aging, National Institutes of Health of Bethesda, MD. At the CWRU School of Medicine he was Professor of Neurology, Radiology and Psychiatry and Chief of the Laboratory of Neurogeriatrics from 1990 to 2008. In December of 2008 he joined the faculty of the University of Louisville, as a Professor of Neurology. Dr. Friedland’s work has focused on clinical and biological issues in Alzheimer’s disease and related disorders. Dr. Friedland has authored or coauthored over 200 scientific publications and has current research funding from the National Institutes of Health (National Institute on Aging), as well as several Foundations, Institutes, Corporations and Families. He has had over $1,000,000 of research funding to support his work from 1985-2013.

Clinical Interests

Dementia, Alzheimer’s disease, brain aging, prevention, neurogeriatrics, behavioral neurology

Research Interests

Dr. Friedland’s work has focused on clinical and biological issues in Alzheimer’s disease and related disorders. He was the first to document patterns of abnormal brain metabolism and cerebral blood flow in the disease using positron emission and single photon emission computed tomography. He also contributed the initial studies of magnetic resonance imaging in dementia. The first studies of driving behavior in patients with Alzheimer’s disease came from his group at the NIH. Dr. Friedland has also worked on the patterns of disease occurrence and risk and protective factors, with studies of the Kikuyu in Kenya, Jews and Arabs in Israel, Caucasian and African-American subjects in Ohio and Mexican and European American subjects in Texas. He has documented a series of important determinants of the disease, including physical and mental inactivity, smoking, obesity, and diet. This work has focused on interactions of genetic and environmental lifestyle elements. These studies have led to a National Health Literacy Program working to enhance public awareness about the disease and how lifestyle modifications may influence risk. His group also participated in the discovery of the important Alzheimer’s disease risk factor gene, SORL1. Animal models have been used by Dr Frieldand and his collaborators to better define the biological mechanisms of Alzheimer’s disease in order to develop new treatments. The first demonstration of catalytic antibodies targeting the Alzheimer amyloid Beta protein in the blood was published by his group in 2007. In 2008 Dr Friedland and colleagues reported the first demonstration of a possible interaction involving molecular mimicry between protective anti-amyloid antibodies and exposure to a plant virus. Current studies are devoted to developing immunological approaches to the treatment of both Alzheimer and Parkinson’s diseases.

Academic and Community Education Activities

1. On Sep 17, 2011 at the Crowne Plaza we hosted a meeting for the community called “The Journey: Alzheimer’s Disease and Caregiving”. The session was attended by about 120 persons, many of whom were family caregivers. The talks were well received by the audience and there were many questions asked during the Q&A session as well as during the lunch break. The links below are video recordings of the talks. We plan to continue to host such educational meetings regarding Alzheimer disease and other dementias for the community each year.

Alzheimer Meeting Sep 17th 2011 Agenda Download PDF (453KB)

1. Opening Remarks (Suhas Kulkarni and Helen Lang): http://louisville.edu/television/Med/Alzheimers/OpeningRemarks1.asx
2. Dr Obisesan: http://louisville.edu/television/Med/Alzheimers/Obiesesan1.asx
3. Dr Robert Friedland: http://louisville.edu/television/Med/Alzheimers/Friedland1.asx
4. Dr. Karen Robinson: http://louisville.edu/television/Med/Alzheimers/Robinson1.asx
5. Dr Dee Antimisiaris: http://louisville.edu/television/Med/Alzheimers/Antimisiaris1.asx
6. Dr David Casey: http://louisville.edu/television/Med/Alzheimers/Casey1.asx
7. Johanna Weiss (Alzheimer Association, Louisville): http://louisville.edu/television/Med/Alzheimers/Weiss1.asx
8. Q&A http://louisville.edu/television/Med/Alzheimers/QandA1.asx
9. Panel Discussion: http://louisville.edu/television/Med/Alzheimers/Panel1.asx

Louisville Free Pubic Library series: Boom Time Series Jan 18, 2012
Dr. Robert Friedland. “Your brain: How to reduce your risk”
http://louisville.edu/television/Med/Alzheimers/Friedland.asx

Neurology Grand Rounds Mar 16, 2012
Dr. Robert Friedland. The Framing of the Concept of Dementia:
From Emil Kraepelin to National Institute of Aging
http://louisville.edu/television/Med/GrandRounds/NGR031612.asx

Selected Publications

1. Friedland RP, Yahr MD. Meningoencephalopathy secondary to infectious mononucleosis. Archives ofNeurology 34:186-188, 1977.

2. Friedland RP, Whetsell W. Clinicopathologic notes: Adrenocortical carcinoma with Cushing's syndrome, organic psychosis and aphasia, Mount Sinai Journal of Medicine 45:509-523, 1978.

3. Friedland RP, Grant S. Hematocrit, viscosity and cerebral blood flow. American Heart Journal 97:404-405, 1979.

4. Yen CK, Yano Y, Budinger TF, Friedland RP, Derenzo SE, Huesman RH, O'Brien HA. Brain tumor evaluation using RB-82 and positron emission tomography. Journal of Nuclear Medicine 23:532-537, 1982.

5. Cooper JA, Nakada T, Knight RT, Friedland RP. Autosomal dominant motor system degeneration in a black family. Annals of Neurology 14:585-587, 1983.

6. Friedland RP, Budinger TF, Yano Y, Huseman R, Knittel B, Derenzo, SE, Koss, B, Ober BA. Regional cerebral metabolic alterations in Alzheimer-type dementia: Kinetic studies with 18-fluorodeoxyglucose. Journal of Cerebral Blood Flow and Metabolism 3, Suppl 1:S510-511, 1983.

7. Friedland RP, Mathis CA, Budinger TF, Moyer BR. Labeled choline and phosphorylcholine: Bodydistribution and brain autoradiography. Journal of Nuclear Medicine 24:812-815, 1983.

8. Friedland, RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman R, Derenzo S.Regional cerebral metabolic alterations in dementia of the Alzheimer-type: positron emission tomography with 18-fluorodeoxyglucose. Journal of Computer Assisted Tomography 7:590-598, 1983.

9. Jones A, Friedland RP, Koss B, Ober BA, Stark, L. Saccadic intrusions in Alzheimer-type dementia. Journal of Neurology 229:189-194, 1983.

10. Friedland RP, Yano Y, Budinger TF, Ganz E, Huesman RH, Derenzo SE, Knittel B. Quantitative evaluation of blood brain barrier integrity in Alzheimer-type dementia: Positron emission tomographic studies  with rubidium-82. European Neurology 22, Suppl 2:19-20, 1983.

11. Koss E, Ober BA, Delis D, Friedland RP. The Stroop color-word test: Indicator of dementia severity. International Journal of Neurosciences 24:53-61, 1984.

12. Friedland RP, Prusiner S, Jagust W, Budinger TF. Bitemporal hypometabolism in Creutzfeldt-Jakob disease: Positron emission tomography with 18F-2-fluorodeoxyglucose. Journal of Computer Assisted Tomography 8:978-981, 1984.

13. Friedland RP, Budinger TF, Brant-Zawadzki MN, Jagust WJ. The diagnosis of Alzheimer-type dementia: a preliminary comparison of PET and proton NMR imaging. Journal of the American Medical Association 252:2750-2752, 1984.

14. Friedland RP, Budinger TF, Koss E, Ober BA. Alzheimer's disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neuroscience Letters 53:235-240, 1985.

15. Ober BA, Koss E, Friedland RP, Delis DC. Processes of verbal memory failure in Alzheimer-type dementia. Brain and Cognition 4:90-103, 1985.

16. Jagust WJ, Friedland RP, Budinger TF. Positron emission tomography differentiates normal pressurehydrocephalus from Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 48:1091-1096, 1985.

17. Koss E, Friedland RP, Ober BA, Jagust WJ. Differences in lateral hemispheric asymmetries of glucose utilization between early-and late-onset Alzheimer-type dementia. American Journal of Psychiatry 142:638-640, 1985.

18. Jagust WJ, Friedland RP. Positron emission tomography in the study of Alzheimer's disease. VA Practitioner 2:55-66, 1985.

19. Friedland RP, Koss E, Jagust WJ. Lateral hemispheric asymmetries of glucose use in Alzheimer's disease: Relationships to behavior, age of onset and prognosis. Journal of Cerebral Blood Flow and Metabolism 5, (Suppl 1):S123-124, 1985.

20. Friedland RP, Jagust WJ, Budinger TF, Huesman RH, Knittel B. Methodological factors affecting the accuracy of metabolic measurements in PET studies with (18F)-2-fluoro-2-deoxy-D-glucose (FDG). Journal of Cerebral Blood Flow and Metabolism 5(Suppl. 1):S609-610, 1985.

21. Ober BA, Dronkers NF, Koss E, Friedland RP, Delis DC. Retrieval from semantic memory in Alzheimer-type dementia. Journal of Clinical and Experimental Neuropsychology 8:75-92, 1986.

22. Lakshminarayanan V, Friedland RP, Muller EC, Koss E, Stark L. The vestibular-ocular reflex in Alzheimer's disease. Neuro-ophthalmology 6:205-208, 1986.

23. Jagust WJ, Budinger TF, Huesman RH, Friedland RP, Mazoyer BM, Knittel BL. Methodological factors affecting PET measurements of cerebral glucose metabolism. Journal of Nuclear Medicine 27:1358-1361, 1986.

24. Luxenberg J, Friedland RP, Rapoport SI. Quantitative X-ray computed tomography (CT) in dementia of the Alzheimer type (DAT). Canadian Journal of the Neurological Sciences 13:570-572, 1986.

25. Haxby JV, Grady CL, Friedland RP, Rapoport SI. Neocortical metabolic abnormalities precede nonmemory cognitive impairments in early dementia of the Alzheimer type: Longitudinal confirmation. Journal of Neural Transmission 24:49-53, 1987.

26. Grady C, Haxby JV, Horwitz B, Sundaram M, Berg G, Schapiro M, Friedland RP, Rapoport SI. A longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. Journal of Clinical and Experimental Neuropsychology 10:576-596, 1988.

27. Kaye JA, May C, Daly E, Atack JR, Sweeney DJ, Luxenberg JS, Kay AD, Kaufman S, Milstein S, Friedland RP, Rapoport SI. Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features. Neurology 38:554-557, 1988.

28. Rainero I, May C, Kaye JA, Friedland RP, Rapoport SI. Cerebrospinal fluid alpha melanocyte stimulating hormone in dementia of the Alzheimer type. Neurology 38:1281-1284, 1988.

29. Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral glucose utilization in Alzheimer's disease. Neurology 38:909-912, 1988.

30. Luxenberg J, Plato CC, Fox KM, Friedland RP, Rapoport SI. Digital and palmar dermatoglyphics indementia of the Alzheimer's type. Journal of Medical Genetics 30:733-740, 1988.

31. Koss E, Weiffenbach JM, Haxby JV, Friedland RP. Olfactory detection and identification performance in Alzheimer's disease. Neurology 38:1228-1232, 1988.

32. Friedland RP, Horwitz B, Koss E. Measurement of disease progression in Alzheimer's disease.Neurobiology of Aging 9:95-97, 1988.

33. Luxenberg J, Swedo S, Flament MF, Friedland RP, Rapoport SI. Neuroanatomic abnormalities inobsessive compulsive disorder detected with quantitative x-ray computed tomography. American Journal of Psychiatry 145: 1089-1093, 1988.

34. Friedland RP, Koss E, Haxby JV, Grady C, Luxenberg J, Schapiro MB, Kaye J. The clinical and biologicalheterogeneity of Alzheimer's disease. Annals of Internal Medicine 109:298-311, 1988.

35. Friedland RP, Koss E, Kumar A, Gaine S, Metzler D, Haxby JV, Moore A, Rapoport SI, Motor vehiclecrashes in dementia of the Alzheimer type. Annals of Neurology 24:782-786, 1988.

36. Kumar A, Koss E, Metzler D, Moore A, Friedland RP. Behavioral symptomatology in dementia of theAlzheimer type. Alzheimer's Disease and Associated Disorders: An International Journal 2:363-365, 1988.

37. Rainero I, Kaye JA, May C, Durso R, Katz DI, Albert ML, Wolfe N, Pinessi L, Friedland RP, Rapoport SI.Alpha-melanocyte stimulating hormone immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Archives of Neurology 45:1224-1227, 1988.

38. Haxby JV, Grady CL, Koss E, Horwitz B, Shapiro M, Friedland RP, Rapoport SI. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology 38:1853-1863, 1988.

39. Kaye JA, May C, Atack JR, Daly E, Sweeney DL, Beal MF, Kaufman S, Milstein S, Friedland RP, Rapoport SI. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Annals of Neurology24:647-650, 1988.

40. Friedland RP. Positron imaging in the dementing illnesses. Journal of Neuropsychiatry and Clinical Neurosciences 39:309-310, 1989.

41. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland RP, Rapoport SI,Rapoport JL. Cerebral glucose metabolism in childhood-onset obsessive compulsive disorder. Archives of General Psychiatry 46:518-523, 1989.

42. Friedland RP, Jagust WJ, Huesman RH, Koss E, Knittel B, Mathis CA, Ober BA, Mazoyer BM, Budinger TF. Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurology 39:1427-1434, 1989.

43. Friedland RP. "Normal" pressure hydrocephalus and the saga of the treatable dementias. Journal of the American Medical Association 262:2577-2581, 1989.

44. Grady CL, Berg G, Carson RE, Daube-Witherspoon WE, Friedland RP, Rapoport SI. Quantitative comparison of glucose metabolic rates from two position emission tomographs. Journal of Nuclear Medicine 30:1386-1392, 1989.

45. Schapiro MB, Luxemberg JS, Kaye JA, Haxby JV, Friedland RP, Rapoport SI. Serial quantitative CT analysis of brain morphometrics in adult Down's Syndrome at different ages. Neurology 39:1349-1353, 1989.

46. Friedland RP. Position emission tomography in dementia. Seminars in Neurology 9:338-344, 1989.

47. Friedland RP, May C, Dahlberg J. The viral hypothesis of Alzheimer's Disease: Absence of antibodies to lentiviruses. Archives of Neurology 47:177-178, 1990.

48. Ship JA, DeCarli C, Friedland RP, Baum B. Diminished submandibular salivary flow in dementia of the Alzheimer type. Journal of Gerontology 45:M61-66, 1990.

49. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid production is reduced in healthy aging. Neurology 40:500-503, 1990.

50. Friedland RP, Luxenberg JS, Koss E. A quantitative study of intracranial calcification in dementia of the Alzheimer type. International Psychogeriatrics 2:37-43, 1990.

51. Kaye JA, Grady CL, Haxby JV, Moore A, Friedland RP. Plasticity in the aging brain: Reversibility of anatomic, metabolic and cognitive deficits in normal pressure hydrocephalus following shunt surgery. Archives of Neurology 47:1336-1341, 1990.

52. Schapiro MB, Grady CL, Kumar A, Herscovitch P, Haxby JV, Moore AM, White B, Friedland RP, Rapoport SI. Regional cerebral glucose metabolism is normal in young adults with Down Syndrome. Journal of Cerebral Blood Flow and Metabolism 10:199-206, 1990.

53. May C, Haber M, Young SH, Tomai TP, Csako G, Friedland RP. Osmoregulation in Alzheimer's Disease.Dementia 1:90-94, 1990.

54. Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Archives of Neurology 47:753-760, 1990.

55. Schapiro MB, Kumar A, White B, Fox D, Grady CL, Haxby JV, Friedland RP, Rapoport SI. Dementia without mental retardation in mosaic translocation Down Syndrome. Brain Dysfunction 3:165-174, 1990.

56. Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. Journal of Psychiatric Research 24(2):97-109, 1990.

57. Kumar A, Schapiro MB, Grady CL, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI. High resolution studies of cerebral glucose metabolism in Alzheimer's disease. Neuropsychopharmacology 4:35-46, 1991.

58. Friedland RP, Iadecola C. Roy and Sherrington (1890): A centennial re-examination of "On the regulation of the blood-supply of the brain". Neurology 41:10-14, 1991. (Recipient of Lawrence McHenry Award, American Academy of Neurology, 1990)

59. Koss E, Haxby JV, DeCarli C, Schapiro MB, Friedland RP, Rapoport SI. Patterns of performancepreservation and loss in healthy aging. Developmental Neuropsychology 7:99-113, 1991.

60. Ober BA, Jagust WJ, Koss E, Delis DC, Friedland RP. Visuoconstructive performance and regionalcerebral glucose metabolism in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology 13:752-772, 1991.

61. DeCarli C, Fugate L, Falloon J, Eddy J, Katz D, Friedland R, Rapoport S, Brouwers P, Pizzo P. Braingrowth and cognitive improvement in children with HIV-induced encephalopathy after six months of continuous infusion AZT therapy. Journal of the Acquired Immune Deficiency Syndrome 4:585-592, 1991.

62. Godec MS, Asher DM, Masters CL, Kozachuk WE, Friedland RP, Gibbs CJ, Gajdusek DC, Rapoport SI,Schapiro MB. Evidence against the transmissibility of Alzheimer's Disease. Neurology 41:1320, 1991.

63. Majocha RE, Reno JM, Friedland RP, Van Haight C, Lyle LR, Marotta CA. Development of a monoclonal antibody specific for ß/A4 Amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy Journal of Nuclear Medicine 33:2184-2189, 1992.

64. Friedland RP. Alzheimer's disease: Clinical features and differential diagnosis Neurology 43 (suppl4):S45-S51, 1993.

65. Friedland RP, Koss E, Lerner A, Hedera P, Jagust WJ, Ellis W, Dronkers N, Ober A. Functional imaging, the frontal lobes, and dementia. Dementia 4:192-203, 1993. (Abstracted in NeuroCase 4:8, 1998)

66. Lerner A, Friedland RP, Whitehouse PJ. Editorial: Role of biological markers of Alzheimer's Disease. Alzheimer's Disease: An International Journal 6:197-200, 1993.

67. Friedland RP, Lerner AJ, Hedera P, Brass EP, Encephalopathy associated with bismuth subgallate therapy. Clinical Neuropharmacology 16:173-176, 1993.

68. Drachman DA, Swearer JM, Barnes HJ, Woodward BM, Peterson KE, Moonis M, Weintraub S, MorecroftK, Guinessey J, Acar D, Sandson T, Blass J, Nolan K, Ryan B, Morris JC, Ball LA, Friedland RP, Martin R, DeKosky ST, FuQua-Whitley D, Lineman DA, Castle J. Driving and Alzheimer's Disease: The risk of crashes. Neurology 43:2448-2456, 1993.

69. Lai S, Hopkins AL, Haacke EM, Li D, Wasserman BA, Buckley P, Friedman L, Meltzer H, Hedera P,Friedland RP. Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T: Preliminary results. Magnetic Resonance in Medicine 30:387-392, 1993.

70. Hedera P, Friedland RP. Duane's syndrome with giant aneurysm of the vertebral basilar arterial junction. Journal of Clinical Neuro-ophthalmology 13:271-274, 1993.

71. Friedland RP. Editorial: Epidemiology, education, and the ecology of Alzheimer's disease. Neurology 43:246-249, 1993 (published also in Portuguese in: Cadernos IPUB Envelhecimento e Saude Mental, Ed. By A. Leibing, Instituto de Psiquiatria, UFRJ, No. 10, 1999, pp. 165-174.

72. Friedland RP. Epidemiology and the multiple determinants of Alzheimer's disease. Neurobiology of Aging 15:239-241, 1994.

73. Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-Aß monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Molecular Neurobiology 9:107-113, 1994.

74. Lerner AJ, Koss E, Patterson MB, Hedera P, Ownby RL, Friedland RP, Whitehouse PJ. Concomitants of visual hallucinations in Alzheimer's disease. Neurology 44:523-527, 1994.

75. Hedera P, Cohen ML, Lerner AJ, Friedland RP. Dementia preceding motor symptoms in Parkinson's disease: A case study. Neuropsychiatry, Neuropsychology and Behavioral Neurology 7:67-72, 1994.

76. Weinstein EA, Friedland RP, Wagner EE. Denial/unawareness of impairment and symbolic behavior in Alzheimer's disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology 7:176-184, 1994.

77. Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Abnormal connectivity of the visual pathways in human albinos demonstrated by susceptibility sensitized magnetic resonance imaging. Neurology 44:1921-1926, 1994.

78. Haacke EM, Hopkins A, Lai S, Buckley P, Friedman L, Meltzer H, Hedera P, Friedland RP, Klein S,Thompson L, Detterman D, Tkach J, Lewin JS. 2D and 3D high resolution gradient echo functional imaging of the brain venous contributions to signal in motor cortex studies. NMR in Biomedicine 7:54-62, 1994.

79. Hedera P, Lerner AJ, Castellani R, Friedland RP. Concurrence of Alzheimer's disease, Parkinson's disease; diffuse Lewy body disease and amyotrophic lateral sclerosis. Journal of Neurological Sciences 128:219-224, 1995.

80. Hedera P, Wu D, Lewin JS, Miller D, Lerner AJ, Friedland RP. Temporal patterns of uncoupling between oxidative metabolism and regional cerebral blood flow demonstrated by functional magnetic resonance imaging. Investigative Radiology 30:625-633, 1995.

81. Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. American Journal of Pathology 148:2083-95, 1996.

82. Hedera P, Lai S, Lewin JS, Haacke EM, Wu D, Lerner AJ, Friedland RP. Assessment of cerebral blood flow reserve using functional magnetic resonance imaging. Journal of Magnetic Resonance Imaging 6:718-725, 1996.

83. Thal LF, Carta A, Clarke WR, Ferris SH, Friedland RP, et al. A one-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer’s disease. Neurology 47:705-711, 1996.

84. Ogeng’o JA, Cohen DL, Sayi G, Matuja WB, Chande HM, Kitinya J, Kimani JK, Friedland RP, Mori H, Kalaria RN. Cerebral amyloid ß protein deposits and other alzheimer lesions in non-demented elderly East Africans. Brain Pathology 6:101-107, 1996.

85. Salomon A, Jao S-C, Marcinowski K, Friedland RP, Zagorski M. Nicotine inhibits amyloid formation by the ß-peptide. Biochemistry 35:13568-78, 1996.

86. Ford AB, Mefrouche Z, Friedland RP, Debanne SM. Smoking and cognitive impairment: A populationbased study. Journal of the American Geriatrics Society 44:905-909,1996.

87. Lewin JS, Friedman L, Wu D, Miller D, Thompson L, Klein S, Wise A, Hedera P, Buckley P, Friedland RP. Cortical localization of human sustained attention: Detection with functional MR using a visual vigilance paradigm. Journal of Computer Assisted Tomography 20:695-701, 1996.

88. Lundberg C, Johansson K, Ball K, Bjerre B, Blomqvist C, Braekhus A, Brouwer W, Bylsma F, Carr D,Englund L, Friedland RP, et al. Dementia and driving - an attempt at consensus. Alzheimer’s Disease and Associated Disorders 11:28-37, 1997.

89. Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders 11:16-20, 1997.

90. Friedland RP. Strategies for driving cessation in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders 11:73-75, 1997.

91. Hedera P, Friedland RP. Cerebral autosomal dominant anteriopathy with subcortical infarcts and leukoencephalopathy: Study of two American families with predominant dementia. Journal of Neurological Sciences 146:27-33, 1997.

92. Lerner AJ, Koss E, Debanne SM, Rowland DY, Smyth KA, Friedland RP. Interactions of smoking historywith estrogen replacement therapy as protective factors for Alzheimer’s disease (Letter). Lancet 349:403-404, 1997.

93. Kalaria RN, Ogeng’o JA, Patel NB, Sayi JG, Kitinya JN, Chande HM, Matuja WB, Mtui EP, Kimani JK,Premkumar DRD, Koss E, Gatere S, Friedland RP. Evaluation of risk factors for Alzheimer’s disease in elderly east Africans, Brain Research Bulletin 44:573-577, 1997.

94. Sayi JG, Patel NB, Premkumar DRD, Adem A, Winblad B, Matuja WB, Mtui EP, Gatere S, Friedland RP Koss E, Kalaria RN. Apolipoprotein E polymorphism in elderly East Africans. East African Medical Journal 74:668-670, 1997.

95. Hedera P, Wu D, Collins S, Lewin JS, Miller D, Lerner AJ, Klein S, Friedland RP. Sex and EEG synchronization after photic stimulation predict signal changes in the visual cortex detected on functional MR images. American Journal of Neuroradiology, 19:853-857, 1998.

96. Perry G, Smith MA, McCann CE, Siedlak SL, Jones P, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer Disease. Brain Research 791:63-66, 1998.

97. Muzic RF, Berridge MS, Friedland RP, Zhu N, Nelson AD. Quantification of specific binding of [11C] nicotine in human brain using PET. Journal of Nuclear Medicine 39:2048-2054, 1998.

98. Friedland RP, Farrer LA, Cupples LA, Debanne SM, Lerner AJ, and the MIRAGE Study Group. Smoking and risk of Alzheimer’s disease (letter) Lancet 352:819, 1998.

99. Friedland RP, McMonagle J. Medical Legal Aspects of Alzheimer’s disease. Journal of the Cleveland Bar Association 70:69, 1999.

100. Shi J, Perry G, Aliev G, Smith MA, Ashe KH, Friedland RP. Serum amyloid P is not present in amyloid ß deposits of a transgenic animal model. NeuroReport 10:3229-3232, 1999.

101. Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: The insidious pathogenesis of Alzheimer’s disease. Neurobiology of Aging 21:357-361, 2000.

102. Aliev G, Shi J, Perry G, Friedland RP, LaManna J. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. The Anatomical Record 259:1-10, 2000.

103. Lerner AJ, Elston R, Chen C, Friedland RP. Response of the hypothalamic-pituitary-adrenal axis to lumbar puncture induced stress. Journal of Alzheimer’s Disease 2:193-198, 2000.

104. Bowirrat A, Friedland, RP, Chapman J, Korczyn AD. Expedited publication:The very high prevalence of Alzheimer’s disease in an Arab population is not explained by high APOE e4 allele frequency. Neurology 55:731, 2000.

105. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-Beta deposition in Down’s syndrome. Journal of Neuropathology and Experimental Neurology 59:1011-1017,2000.

106. Aliev, G, Smith, MA, Turmaine, M, Neal ML, Zimina, TV, Friedland, RP, Perry, G, LaManna, JC, Burnstock, G. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Experimental and Molecular Pathology 71, 40-54, 2000

107. Zeng H, Shao H, Menon NK, Yang J, Salomon AR, Friedland RP, Zagorski M. Nicotine and amyloid formation. Biological Psychiatry 49:248-257, 2001.

108. Demissie S, Green RC, Mucci L, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K, Smith T, Lautenschlager N, Friedland RP, Cupples LA, Farrer LA. Reliability of information collected by proxy in family studies of Alzheimer’s disease. Neuroepidemiology 20:105-111, 2001.

109. Seyidova D, Aliev G, Neal ML, Shi J, Vigano T, Hernandez A, Folco G, Soas AH, Smith MA, Perry G,LaManna JC, Friedland RP.The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cells in vitro. Journal of Submicroscopic Cytology and Pathology 33(1-2):141-9, Jan-Apr 2001.

110. Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer’s type dementia in an elderly Arab population. European Neurology 8:119-123, 2001.

111. Petot GJ, Debanne SM, Reidel TM,. Smyth KA, Cook TB, Koss E, Lerner AJ, Friedland RP. Surrogate responders do not introduce bias in a case control study of dietary risk factors for Alzheimer’s disease. Journal of the American Dietetic Association 102:848-850, 2002.

112. Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot GJ, Debanne SM. Patients with Alzheimer’s disease have reduced premorbid activities compared to healthy controls. Proceedings of the National Academy of Sciences (USA) 98:3440-3445, 2001.

113. Aliev, G, Seyidove, D, Neal, ML, Shi, J, Vigano, T, Hernandez, A, Folco, G., Soas, AH, Zimina, TV, Smith, MA, Perry, G, Lamanna, JC, Friedland, RP. The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cell in vitro. Journal of Submicroscopic Cytology and Pathology 33:141-149, 2001.

114. Debanne SM, Petot GJ, Li J, Koss E, Lerner AJ, Riedel TM, Rowland DY, Smyth KA, Friedland RP. On the use of surrogate respondents for controls in a case-control study of Alzheimer’s disease. Journal of the American Geriatrics Society 49:1-5,2001.

115. Mizrahi E, Fritsch T, Smyth KA, Friedland RP, Lerner AJ. Medication use in Alzheimer’s Disease. Clinical Gerontologist 24:75-84, 2001

116. Aliev G, Smith MA, Zimina TV, Neal ML, Lamb BT, Nunomura A, Seyidova D, Vinters HV, LaManna JC, Perry G, Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer’s’ disease. Brain Pathology 12:21-35, 2002.

117. Fritsch T, McLendon MJ, Smyth KA, Lerner AJ, Chen CH, Petot GJ, Debanne SM, Soas A, Friedland RP. Effects of educational attainment on the clinical expression of Alzheimer’s disease: Results from a research registry. American Journal of Alzheimer’s Disease and Other Dementias 16:369-376, 2001.

118. Mizrahi E, Jacobsen DW, Friedland RP. Plasma homocysteine: A new risk for Alzheimer’s disease? Israel Medical Association Journal 4:1-4,2002.

119. Friedland RP, Petot GJ, Farrer LF. Diet and Alzheimer’s disease. Arab Journal of Psychiatry 13:10-17 2002.

120. Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, La Manna JC, Friedland RP. Labeling of cerebral Aβ deposits in vivo using intranasal bFGF and SAP component in mice, Journal of Nuclear Medicine 43:1044-1051, 2002. (Invited Commentary on this paper was published in the same issue: Potential for a sprecific neuroradiological diagnosis of Alzheimer’s disease, Blass JB, Journal of Nuclear Medicine 43:1051-1053, 2002).

121. Aliev G, Smith MA, Perry G, Samedov S, Seyidova D, Friedland RP, La Manna JC, Gasimov EK. The experimental model of Alzheimer’s disease and its selective pharmacological treatments. Academy of Sciences of Azerbaijan Reports 57:112-118, 2001.

122. Friedland RP, Lipid Metabolism, epidemiology and the mechanisms of Alzheimer’s disease. Annals of the New York Academy of Sciences 977:387-390, 2002

123. Bowirrat A, Friedland RP, Farrer L, Baldwin C, Korczyn A. Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 19: 239-245, 2002.

124. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Winters HV, Head E, Perry G, Lamanna JC, Friedland RP, Cotman CW. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Annals of the New York Academy of Sciences 977:45-64, 2002.

125. Aliev G, Smith MA, Seyidova D, Neal ML, Shi J, Loizidou M, Turmaine M, Friedland RP, Taylor I,Burnstock G, Perry G, Lamanna JC. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. J Submicroscopic and Cytological Pathology 34:37-50, 2002

126. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, DeCarli C, Kukull W, Chui H, Edeki T, Griffith P, Friedland RP, Bachman D, Farrer LA: Depression as a risk factor for Alzheimer’s disease: The MIRAGE study. Archives of Neurology 60:753-759,2003.

127. Petot G, Chen C, Traore F, Debanne S, Friedland RP, Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 52:279-281, 2003.

128. Farrer, L.A., Friedland RP, Bowirrat A, Waraska, Korczyn AD, Baldwin CT. Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 20:207-212, 2003.

129. Farrer, LA, Bowirrat, A, Friedland RP, Waraska, K, Korczyn, AD, Baldwin, CT. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Human Molecular Genetics 12:415-422, 2003.

130. Mizrahi EH, Jacobsen DW, Debanne SM, Traore F, Lerner AJ, Friedland RP, Petot GJ. Plasma total homocysteine levels, dietary B6 and folate intake in AD and healthy aging. Journal of Nutrition, Health and Aging 7:160-165, 2003.

131. Bowirrat A, Friedland RP, Korczyn AD, Vascular dementia among elderly Arabs in Wadi Ara, Journal of Neurological Sciences 203-204:73-76, 2003.

132. Friedland RP. Editorial: Fish consumption and the risk of Alzheimer’s disease: Is it time to make dietary recommendations? Archives of Neurology, 60:923-924, 2003.

133. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G. Mitochondria and vascular lesions as a central target for the development of Alzheimer’s disease and Alzheimer-like pathology in transgenic mice. Neurological Research 25:655-674, 2003.

134. Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: Major contributor or decorative response to Alzheimer’s disease pathogenesis. Neurobiology of Aging;25(5):599-602; May-Jun 2004.

135. Petot G, Friedland RP. Diet, lipids and Alzheimer’s disease. Journal of the Neurological Sciences 226:31-33, 2004.

136. Smyth KA, Fritsch T, Cook TB, McClendon MJ, Santillan CE, Friedland RP. Worker functions and traits associated with occupations and the development of Alzheimer’s disease. Neurology 63:498-503, 2004.

137. Mizrahi EH, Bowirrat A, Jacobsen DW, Korczyn AD, Traore F, Petot GJ, Lerner AJ, Debanne SM, Adunsky A, DiBello PM, Friedland, RP. Plasma homocysteine, vitamin B12 and folate in Alzheimer’s patients and healthy Arabs in Israel. Journal of Neurological Sciences 15;227:109-13, 2004.

138. Geula C, Emre M, Friedland RP. The 2nd International Symposium on Alzheimer’s disease and Related Disorders in the Middle East, May 1-3, 2004, Istanbul, Turkey. Amyloid 11:276-280, 2004.

139. Bowirrat A, Cui J, Waraska K, Friedland RP, Oscar-Berman M, Farrer LA, Korczyn A ,association between angiotensin-converting enzyme (ACE) and dementia of the Alzheimer’s type (DAT) in an elderly Arab population in Wadi Ara, Israel. Neuropsychiatric Disease and Treatment, 1:73-76, 2005.

140. Lindstrom HA, Fritsch T, Petot G, Smyth KA, Chen CH, Debanne SM, Lerner AJ, Friedland RP, The relationships between television viewing in midlife and the development of Alzheimer disease in a case-control study, Brain and Cognition 58:157-165, 2005.

141. Lee JH, Friedland RP, Whitehouse PJ, Woo JI. Twenty-four hour rhythms of sleep wake cycle and temperature in Alzheimer’s disease. Journal of Neuropsychiatry and Clinical Neuroscience 16:192-198 2004.

142. Fritsch T, Smyth KA, Debanne SM, Petot G, Friedland RP. Participation in ”novelty seeking” leisure activities and Alzheimer’s disease. Journal of Geriatric Psychiatry and Neurology, 18:134-141, 2005.

143. Sparks DL, Robert Friedland RP (The first 2 authors contributed equally as lead investigators), Petanceska S, Schreurs BG, Shi J, Perry G, Smith MA, Sharma A, DeRosa S, Ziolkowski C, Stankovic G. Trace copper levels in the drinking water, but not zinc or aluminum, influence CNS Alzheimer-like pathology. Journal of Nutrition, Health and Aging 10:247-254, 2006

144. Inzelberg, R, Mazarib A, Masarwa, M, Abuful A, Strugatsky R. Friedland, RP Essential tremor prevalence is low in Arabic villages in Israel -Door-to-door neurological examinations. Journal of Neurology 253:1557-1560, 2006.

145. Meng Y, Baldwin CT, Bowirrat A, Waraska K, Friedland RP, Farrer LA, Associations in the angiotensin-converting enzyme gene with Alzheimer’s disease in an Israeli-Arab community. American Journal of Human Genetics 78:871-877, 2006.

146. Inzelberg, R, Schechtman, E, Abuful, A, Masarwa, M, Mazarib A, Strugatsky R, Farrer LF, Friedland RP. Education effects on cognitive function in a healthy aged Arab population. International Psychogeriatrics 2006:1-11, 2006.

147. Kishikawa Y, Friedland RP, Socio-cultural background of suicide in Alzheimer’s disease – A cross cultural study of two Alzheimer’s disease patients in the United States and Japan. International Psychogeriatrics (in press).

148. Akomolafe A, Lunetta KL, Erlich PM, Cupples LA, Baldwin CT, Huyck M, Green RC, Farrer LA and the MIRAGE Study Group (including Friedland RP). Genetic association between endothelial nitric oxide synthase and Alzheimer’s disease. Clinical Genetics 70:49-56, 2006.

149. Erlich PE, Lunetta KL, Cupples LA , Huyck M, Green RC, Baldwin CT, Farrer LA , and the MIRAGE Study Group (including RP Friedland) Polymorphisms in the PON gene cluster are associated with Alzheimer disease, Human Molecular Genetics 15:77-85, 2006.

150. Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA for the MIRAGE Study (including Friedland RP). Statin use and the risk of Alzheimer’s disease: The MIRAGE Study. Alzheimer’s & Dementia 2:96-103, 2006

151. Rogaeva E, Meng Y, Leen JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland R, Inzelberg R, Hampe W, Bujo H, Song Y, Andersen O, Graff-Radford N, Petersen R, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer’s Disease. Nature Genetics 39:168-177, 2007.

152. Petot GJ, Vega U, Traore F, Fritsch T, Debanne SM, Friedland RP, Lerner AJ Height and Alzheimer’s disease: Findings from a case-control study. Journal of Alzheimer’s Disease 11:337–341, 2007.

153. Fritsch T, McClendon MJ, Smyth KA, Lerner AJ, Friedland, RP, Larsen J. Cognitive functioning in healthy aging: The role of reserve and lifestyle factors early in life. The Gerontologist 47:307-22,2007.

154. Friedland RP, Armon C, Editorial - Tales of Pacific tangles: Cycad exposure and Guamanian neurodegenerative diseases, Neurology 68:1759-761, 2007.

155. Huang J, Friedland RP, Auchus AP, Diffusion tensor imaging of normal appearing white matter in MCI and early AD: Preliminary evidence of axonal degeneration in temporal lobe. American Journal of Neuroradiology 28:1943-48, 2007,

156. Bonda DJ, Webber KM, Siedlak SL, Perry G, Friedland RP, Smith MA. The pathology of Alzheimer's disease elicits an in vivo immunological response. American Journal of Immunology 3: 10-14, 2007.

157. Goodenowe DB, Cook LL, Liu J, Yingshen Lu,. Jayasinghe DA, Pearson W.K. Ahiahonu, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner AL, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. Journal of Lipid Research 48:2485-98,2007.

158. Friedland RP, Emre M, Geula C. The Third International Symposium on Alzheimer’s Disease and Related Disorders in the Middle East, Istanbul, Turkey, October 1-2, 2005 Amyloid 14:161-168, 2007.

159. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA,Edmundson AB, Weksler ME, Paul S. Autoantibody catalyzed hydrolysis of amyloid beta peptide. Journal of Biological Chemistry 283:4714-22, 2008.

160. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Sudhir S Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease Autoimmunity Reviews 7:391-7, 2008.

161. Gustaw KA,. Garrett MR , Lee H-G, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP,. Smith MA Antigen-Antibody Dissociation in Alzheimer Disease: A Novel Approach to Diagnosis. Journal of Neurochemistry 2008;106:1350-6. Epub 2008 May 12.

162. Friedland RP, Tedesco JM, Wilson AC, Atwood CS, Smith MA, Perry G, Zagorski G. Antibodies to the potato virus Y bind the Aβ peptide: Immunochemical and NMR studies. Journal of Biological Chemistry 283:22550-22556, 2008 (Epub 5/27/08).

163. Chen CH, Mizuno T, Elston R, Kariuki MM, Hall K, Unverzagt F, Hendrie H, Gatere S, Kioy P, Patel NB,Friedland RP, Kalaria RN. A comparative study to screen dementia and APOE genotypes in an ageing East African population. Neurobiol Aging. 31:732-740,2010.

164. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P; World Federation of Neurology Dementia Research Group. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors Lancet Neurol. 2008 ;7:812-26. Epub 2008 Jul 28.

165. Cuenco K, Lunetta KL, Baldwin CT, McKee AC, Guo J, Cupples LA, Green RC, St George-Hyslop PH, Chui H, DeCarli C, Farrer LA; MIRAGE Study Group(including RP Friedland) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Archives of Neurology. 2008;65:1640-8.

166. Glik A, Masarwa M, Abuful A, Deeb A, Strugatsky R, Farrer LA, Friedland RP, Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. Inzelberg R Movement Disorders. 2008. [Epub ahead of print].

167. Cuenco K, Friedland R, Baldwin C, Jianping G, Varadarajan B, Lunetta K, Cupples A, Green R, DeCarli C, Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Farrer L Neurobiology of Aging. 2011;32:249-56.

168. Friedland RP, Brayne. What should the pediatrician know about Alzheimer’s disease? Journal of Developmental and Behavioral Pediatrics 30:239-41, 2009

169. Friedland RP, Petersen RB, Rubenstein R. Bovine spongiform encephalopathy and aquaculture. Journal of Alzheimer’s Disease. 2009 Jun;17:277-9. Mar 6, 2009.

170. Hardwick A, Rucker, JC ,Cohen M L, Friedland, RP. Gustaw-Rothenberg K,; Riley, David E, Leigh RJ. Evolution of ocular motor and clinical findings in autopsy-proven Richardson’s syndrome. Neurology 2009, 15;73:2122-4.

171. Israeli-Korn SD, Masarwa M, Schechtman E, Abuful A, Strugatsky R, Avni S, Farrer LA, Friedland RP,Inzelberg R. Hypertension increases the probability of Alzheimer’s disease and of mild cognitive impairment in an Arab community in Northern Israel. Neuroepidemiology 2010;34:99-105.

172. Llewellyn DJ, Langa KM, Friedland RP, Lang IA. Serum albumin concentration and cognitive impairment. Current Alzheimer Research. 7:91-96,2010.

173. Keage HA, Carare RO, Friedland RP, Ince PG, Love S, Nicoll JA, Wharton SB,Weller RO, Brayne C. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BioMedCentral Neurology. 2009 Jan 13;9:3.

174. Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA; for the MIRAGE Study Group.Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiology of Aging (2011) 32:249-56

175. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, .......Friedland RP, ........et al.. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proceedings of the National Academy of Sciences U S A. 2009;106:20954-20959.

176. Geula C, Efthymiopoulos S, Friedland RP, Meeting Report: The 4th International Symposium on Alzheimer’s Disease and Related Disorders in the Middle East, October, 2007, Athens, Greece, Amyloid, 2010;17:86-90.

177. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL.......Friedland RP, ........et al... Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310-23. Epub 2008 Nov 28.

178. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, .......Friedland RP, ........et al... (206 collaborators). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355-65. Epub 2009 Mar 31

179. Rexroth, DF, Friedland, RP Lessons learned regarding recruitment to the National African American Alzheimer’s Disease Health Literacy Program. Alzheimer’s Disease and Associated Disorders 17:86-90, 2010.

180. Hunter S, Friedland RP, Brayne C Time for a Change in the Research Paradigm for Alzheimer's Disease: The Value of a Chaotic Matrix Modeling Approach. CNS Neuroscience Theraputics Epub ahead of print. CNS Neurosci Ther. 2010;16:254-62.

181. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, .......Friedland RP, ........et al... Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology. 2010 Sep 3. [Epub ahead of print]

182. Perneczky R, Wagenpfeil S, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA, Kurz A; MIRAGE Study Group. Baldwin C, Logue MW, Auerbach S, Wake M, Akomolafe A, Ashley A, Freedman L, Ofili E, Chui H, Duara R, Foroud T, Farlow M, Friedland R, Lerner A, Go R, Obisesan T, Petrovich H, White L, Sabbagh M, Sadovnick D, Tsolaki M. Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology. 2010;75:137-42.

183. Khatchaturian A, Khatchaturian Z, Inzelberg R, Farrer LA, Roses A, Sager M, Friedland RP US-Israel Demonstration Project for a Longitudinal Database for Healthy Aging and Pre-Clinical Dementia: A Perspective, Alzheimer’s Disease and Related Disorders 6:475-481, 2010.

184. Israeli-Korn SD, Massarwa M, Schechtman E, Strugatsky R, Avni S, Farrer LA, Friedland RP, Inzelberg R, Mild cognitive impairment is associated with mild parkinsonian signs in a door-to-door study of an elderly Arab population, Journal of Alzheimer’s Disease,22:1005-1013, 2010.

185. Sherva R, Baldwin CT, Vardarajan B, Cupples A, Lunetta K, Bowirrat A, Inzelberg R, Friedland RP, Farrer LA Identification of Novel Candidate Genes for Alzheimer Disease by Autozygosity Mapping Using Genome Wide SNP Data From an Israeli-Arab Community, Journal of Alzheimer’s Disease, 2011, 23:349-59.

186. Logue MW, Posner H, Green RC, Moline M, Cupples LA, Lunetta KL, Zou H, Hurt SW, Farrer LA, Decarli C; MIRAGE Study Group (including Friedland RP). Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer's disease patients. Alzheimer’s Dementia. 2011;7:493-500; PubMed Central PMCID.

187. Wolk DA, Dickerson BC.... Friedland RP et al....(194 collaborators). Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proceedingss of the National Academy of Sciences USA. 2010;107:10256-61. Epub 2010 May 17. PMID: 20479234; PMC2890481.

188. Ho AJ, Stein JL, ....Friedland RP.... et al...(194 collaborators). Alzheimer's Disease Neuroimaging Initiative. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proceedings of theNational Academy of Sciences USA. 2010;107:8404-9. Epub 2010. PMID: 20404173; PMC2889537.

189. Rimol LM, Agartz I, ....Friedland RP....(194 collaborators). Alzheimer's Disease Neuroimaging Initiative. Sex-dependent association of common variants of microcephaly genes with brain structure. Proceedings of the National Academy of Sciences USA 2010;107:384-8. Epub 2009 Dec 22. PubMed PMID: 20080800; PubMed Central PMCID: PMC2806758.

190. Perneczky R, Wagenpfeil S, ....Friedland RP.....et al...(21 collaborators). MIRAGE Study Group. Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology. 2010;75:137-42. PMID: 20625166; PMCID: PMC2905931.

191. Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RC, Griffith P, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA; Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (including Friedland RP). A comprehensive genetic  association study of Alzheimer disease in African Americans. Arch Neurol. 2011;68:1569-79, PMCID: PMC3356921.

192. Afgin AA, Massarwa M, Schechtman E, Israel-Korn SD, Strugatsky R, Abuful A, Farrer LA, Friedland RP, Inzelberg R. High Prevalence of Mild Cognitive Impairment and Alzheimer's Disease in Arabic Villages in Northern Israel: Impact of Gender and Education. Journal of Alzheimer’s Disease, 2012;29:431-9.

193. Inzelberg R, Afgin AE, Massarwa M, Schechtman E, Israeli-Korn SD, Strugatsky R, Abuful A, Kravitz E,Farrer LA, Friedland RP. Prayer at midlife is associated with reduced risk of cognitive decline in Arabic women. Current Alzheimer Research 2012:10:340-6.PMID: 23116476

194. Rothenberg KG, Piądło R, Nagaraj UD, Veluvolu S, Friedland RP The Complex Picture Test in Dementia, Dementia and Geriatric Cognitive Disrders, Extra, 2:411-7, 2012.

195. Friedland RP, Shah JJ, Farrer LA, Vardarajan B, Rebolledo-Mendez JD, Mok B, Hardy J, Behavioral variant frontotemporal lobar degeneration with amyotrophic lateral sclerosis with a chromosome 9p21 hexanucleotide repeat. Frontiers in Neurogenomics 3:136, 2012, oi:10.3389/fneur.2012.00136

196. Sabbagh MN, Messis C, Friedland RP, Geula C. The 5th International Conference on Alzheimer's Disease and related disorders in the Middle East, 15-17 May 2009, Limassol Cyprus. Journal of Alzheimer’s Disease. 2012;30:711-27. PubMed PMID: 22614876.

197. Vardarajan BN, Bruesegem SY, Harbour ME, St George-Hyslop P, Seaman MN, Inzelberg R, Friedland RP, Farrer LA. Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiology of Aging 2012:33:2231.

198. Friedland RP, Nandi S, A Modest Proposal for a Longitudinal Study of Dementia Prevention (with apologies to Jonathan Swift, 1729) Journal of Alzheimer’s Disease, 2013;33:313-5. doi: 10.3233/JAD-2012-121459

199. Liu R, Vaishnav R, Roberts A, Friedland RP (2013) Humans Have Antibodies against a Plant Virus: Evidence from Tobacco Mosaic Virus. PLoS ONE 8:e60621. doi:10.1371/journal.pone.0060621.

200. Vaishnav RA, Liu R, Chapman J, Roberts AM, Ye H, Rebolledo-Mendez JD, Tabira T, Fitzpatrick AH, Achiron A, Running MP, Friedland RP, Aquaporin 4 Molecular Mimicry and Implications for Neuromyelitis Optica, Journal of Neuroimmunology, 2013;260(1-2):92-8. doi: 10.1016/j.jneuroim.2013.04.015.

201. Rebolledo-Mendez JD, Radhika A. VaishnavRA, Cooper NG, Friedland RP. Cross-kingdom sequence similarities between human micro-RNAs and plant viruses. Communicative and Integrative Biology, 2013;6:e24951. doi: 10.4161/cib.24951. PMID:24228136

202. Raha AA, Vaishnav RA, Friedland RP, Bomford A, Raha-Chowdhury R, The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease. Acta Neuropathologica Communications (2013) 55. doi: 10.1186/2051-5960-1-55. PMID:24252754

203. Fujioka H, Phelix CF, Friedland RP, Zhu X, Perry E, Castellani RJ, Perry G, Apolipoprotein E e4 prevents growth of malaria at the intraerythrocyte stage: Implications for differences in racial susceptibility to Alzheimer’s disease. Journal of Health Care for the Poor and Underserved 2013;24: 70–78.

204. Furman CD, Earnshaw LA, Doukas DJ, Farrer LA, Friedland RP. A case of inappropriate Apolipoprotein E testing in Alzheimer's disease due to lack of an informed consent discussion. American Journal of Alzheimers Disease and Other Dementias 2014;29:590-5. PMID: 24615498.

205. Inzelberg R, Massarwa M, Schechtman E, Strugatsky R, Farrer LA, Friedland RP. Estimating the risk for conversion from mild cognitive impairment to Alzheimer's disease in an elderly Arab community Journal of Alzheimer’s Diease 2015;45:865-71

206. Friedland RP, Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. Journal of Alzheimer’s Disease 2015;45:349-62

207. Werner P, Friedland R, Inzelberg R, Alzheimer's disease and the elderly in Israel: Are we paying enough attention to the topic in the Arab population? American Journal of Alzheimer's Disease and Other Dementias 2015. pii: 1533317515577130.

208. Planque SA, Nishiyama Y, Sonoda S, Lin Y, Taguchi H, Hara M, Kolodziej S, Mitsuda Y, Gonzalez V, Sait HB, Fukuchi KI, Massey RJ, Friedland RP, O'Nuallain B, Sigurdsson EM, Paul S. Specific Amyloid β Clearance by a Catalytic Antibody Construct. Journal of Biological Chemistry 2015. pii: jbc.M115.641738.

209. Banik A, Brown RE, Bamburg J, Lahiri DK, Khurana D, Friedland RP, Chen W, Ding Y, Mudher A, Padjen AL, Mukaetova-Ladinska E, Ihara M, Srivastava S, Padma Srivastava MV, Masters CL, Kalaria RN, Anand A Translation of pre-clinical studies into successful clinical trials for Alzheimer ’s disease: What are the roadblocks and how can they be overcome? Journal of Alzheimer’s Disease 2015 11;47:815-43. doi: 10.3233/JAD-150136. PubMed PMID: 26401762.

210. Miyatani F, Kuriyama N, Watanabe I, Nomura R, Nakano K, Matsui D, Ozaki E, Koyama T, Nishigaki M, Yamamoto T, Mizuno T, Akazawa K, Takada A, Takeda K, Yamada K, Nakagawa M, Ihara M, Kanamur M, Friedland RP, Watanabe Y. Relationship between Cnm-positive Streptococcus mutans and cerebral microbleeds in humans Oral Diseases 2015;21:886-93. doi: 10.1111/odi.12360.

211. Tonomura S, Ihara M, Kawano T,Tanaka T, Okuno Y, Saito S, Friedland RP, Kuriyama N, Nomura R, Watanabe Y, Nakano K, Toyoda K, Nagatsuka K. Intracerebral hemorrhage and deep microbleeds associated with cnm-positive Streptococcus mutans; a hospital cohort study, Scientific Reports (in press).